Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- MHLW Plans to Consolidate Class 2 and 3 OTC Drugs
September 7, 2023
- Exact Sciences’ SaMD to Assess Breast Cancer Recurrence Risk Listed on Sept. 1
September 7, 2023
- Japan Eyes AI-Driven Drug Discovery Project for Cancer, Intractable Diseases
September 7, 2023
- Japan Unveils 2nd Package Strategy for SaMD
September 7, 2023
- Japan Healthcare Spending Renews Record with 46 Trillion Yen in FY2022
September 6, 2023
- Japan to Soon Start Taking Applications for Antibiotic Revenue Guarantee Program
September 6, 2023
- MHLW to Launch Working Group on Drug Supply Info on Sept. 7
September 5, 2023
- 23 Suspected Violations in Promotion Activities Reported in FY2022: MHLW
September 5, 2023
- Dispensing Pharmacy Chief Nabbed for Obstruction of Public Bid
September 4, 2023
- Japan Launches Agency for Infectious Disease Crisis Management
September 4, 2023
- Relief Claims OK’ed for 54 More Deaths after COVID Vaccination
September 4, 2023
- Japan Approves Pfizer’s Omicron XBB.1.5 Vaccine, Moderna’s Still under Review
September 4, 2023
- MHLW Rejigs Organization, Infectious Disease Control Team Boots Up
September 1, 2023
- Industry Requests Rewards for SaMDs that Help Doctors’ Workstyle Reform
September 1, 2023
- Japan to Decide on COVID Health Funding from October, Assuming Shift to Normalcy Next Spring: Minister
September 1, 2023
- MHLW Must Streamline Operations via DX, Improve Staff’s Work-Life Balance: Official
September 1, 2023
- 8 New Cases of Unintentional Xocova Use Among Pregnant Patients, Adding Up to 15
August 31, 2023
- Chuikyo Payer Rep Floats Deferred Price Cuts for PMP upon Generic Entries
August 31, 2023
- MHLW Top Pharma Officer Remains Committed to Fast, Safe Access to Good Drugs
August 31, 2023
- MHLW to Unveil Draft of 2nd Package Strategy for SaMD on Sept. 6
August 31, 2023
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…